Amphastar Pharmaceuticals AMPH Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's operating lease right-of-use assets in other assets?
- Amphastar Pharmaceuticals (AMPH) reported operating lease right-of-use assets in other assets of $71.5M in Q1 2026.
- How has Amphastar Pharmaceuticals's operating lease right-of-use assets in other assets changed year-over-year?
- Amphastar Pharmaceuticals's operating lease right-of-use assets in other assets increased by 56.0% year-over-year, from $45.82M to $71.5M.
- What is the long-term trend for Amphastar Pharmaceuticals's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's operating lease right-of-use assets in other assets has grown at a 16.5% compound annual growth rate (CAGR), from $20.04M to $42.93M.